AMENDMENTS TO THE CLAIMS

1. (previously presented) A compound of formula (I)

or a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, wherein:

 R^1 and R^2 are each independently hydrogen or methoxy, provided R^1 and R^2 are not both hydrogen or both methoxy;

n is 1, 2, 3, or 4;

X is a bond, O, S, C=O, -N(R)-, wherein R is hydrogen or -(C_1 - C_3)alkyl, -C(OH)- or -SO₂; and

Y is benzoxazolyl, benzothiazolyl, benzofurazanyl, benzofuranyl, benzothiadiazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolyl, pyridyl, isatinyl, oxindolyl, indazolyl, indolyl, phenyl, thienyl or furanyl; wherein Y is optionally substituted independently with from one to three halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, thiazolyl or oxadiazolyl.

- 2. (previously presented) The compound of claim 1, wherein X is a bond; and Y is benzofurazanyl, thienyl, pyridyl, or phenyl, wherein said phenyl is optionally substituted independently with one or two halogen, trifluoromethyl, methoxy, -C(=O)CH₃, cyano, -C(CH₃)₂OH, -CH(CH₃)OH, -CH(CF₃)OH, -C(C=O)CF₃, -SO₂NH₂, -C(=O)OCH₃, -CH₂COOH, thiazolyl or oxadiazolyl; or a pharmaceutically acceptable salt thereof.
- 3. (previously presented) The compound of claim 1, wherein X is a bond; n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with

one or two methoxy, halogen, -C(CH₃)₂OH, CH(CF₃)OH or -C(C=O)CF₃; or a pharmaceutically acceptable salt thereof.

- 4. (original) N^2 , N^4 -bis-(3,5-Dimethoxy-benzyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
- N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-thiophen-2-yl-ethyl)-pyrido[2,3-d]pyrimidine-2,4-diamine;
- N^4 -(3,5-dimethoxy-benzyl)- N^2 -2-phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine; N^4 -(3,5-dimethoxy-benzyl)- N^2 -[2-(3,5-dimethoxy-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
- 2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol;
- N^4 -(3,4-dimethoxy-benzyl)- N^2 -[2-(4-fluoro-phenyl)-ethyl]-pyrido[2,3-d]pyrimidine-2,4-diamine;
- N^4 -(3,4-dimethoxy-benzyl)- N^2 -phenethyl-pyrido[2,3-d]pyrimidine-2,4-diamine; or N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.
- 5. (previously presented) A pharmaceutical composition comprising a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.
- 6. (currently amended) A method of treating bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound of formula (I) of claim 1, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutically acceptable salt of said compound or prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.
- 7. (previously presented) The method of claim 6, wherein bone fracture is treated.

8. (previously presented) The method of claim 7, wherein said bone fracture is delayed or non-union bone fracture.

9.-12. (canceled)

13. (currently amended) The method of claim $\frac{12}{6}$, wherein the compound of formula (I) is N^4 -(3,5-dimethoxy-benzyl)- N^2 -(2-pyridin-4-yl-ethyl)-pyrido[2,3-d]pyrimidin-2,4-diamine; 2-(3-{3-[4-(3,4-dimethoxy-benzylamino)-pyrido[2,3-d]pyrimidin-2-ylamino]-propyl}-phenyl)-propan-2-ol; N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug.

14.-15. (canceled)

16. (previously presented) The compound of claim 2, wherein n is 2 or 3; and Y is thienyl, pyridyl or phenyl, wherein said phenyl is optionally substituted independently with one or two methoxy, halogen, -C(CH₃)₂OH, CH(CF₃)OH or -C(C=O)CF₃; or a pharmaceutically acceptable salt thereof.

17. (previously presented) A pharmaceutical composition comprising a compound of claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

18. (currently amended) A method of treating bone fracture or bone defect, occurring individually or together, or of promoting bone in-growth in a mammal in need of such treatment which method comprises administering to said mammal a therapeutically effective amount of a compound claim 4, a prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug; or a pharmaceutical composition comprising said compound claim 4, said prodrug thereof, or a pharmaceutically acceptable salt of said compound or prodrug, and a pharmaceutically acceptable vehicle, carrier or diluent.

19.-20. (canceled)

21. (previously presented) N^4 -(3,4-dimethoxy-benzyl)- N^2 -(3-phenyl-propyl)-pyrido[2,3-d]pyrimidine-2,4-diamine; or a pharmaceutically acceptable salt thereof.